Advanced glycation end-products (AGEs) constitute a non-homogenous, chemically diverse
group of compounds formed either exogeneously or endogeneously on the course of …

The receptor for advanced glycation end products (RAGE) is a non-specific multi-ligand
pattern recognition receptor capable of binding to a range of structurally diverse ligands …

The triggering of gemcitabine (GEM) drug resistance in pancreatic cancer by the receptor for
advanced glycation end products (RAGE) has been demonstrated. Hence, finding a safe …

The receptor for advanced glycation end-products (RAGE) was initially characterized and
named for its ability to bind to advanced glycation end-products (AGEs) that form upon the …

Research on obesity-and diabetes mellitus (DM)-related carcinogenesis has expanded
exponentially since these two diseases were recognized as important risk factors for …

Simple Summary Small cell lung cancer (SCLC) accounts for about 15% of lung cancers
and it has limited therapeutic options and poor prognosis. There has been no real progress …

The involvement of cardiovascular disease in cancer onset and development represents a
contemporary interest in basic science. It has been recognized, from the most recent …

Gemcitabine (GEM) resistance in pancreatic adenocarcinoma mediated by the receptor for
advanced glycation end products (RAGE) has been demonstrated. Therefore, investigating …

The non-enzymatic glycosylation or non-enzymatic covalent modifications (NECMs) or
glycation of cellular proteins result in the generation and accumulation of advanced …

Simple Summary With the mortality rate of pancreatic cancer predicted to rise over the
coming years, it is essential that effective treatment strategies are developed as soon as …